558 related articles for article (PubMed ID: 22476188)
1. Targeting the DNA damage response in oncology: past, present and future perspectives.
Basu B; Yap TA; Molife LR; de Bono JS
Curr Opin Oncol; 2012 May; 24(3):316-24. PubMed ID: 22476188
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of poly(ADP-ribose) polymerase (PARP) and ataxia telangiectasia mutated (ATM) on the chemosensitivity of mantle cell lymphoma to agents that induce DNA strand breaks.
Golla RM; Li M; Shen Y; Ji M; Yan Y; Fu K; Greiner TC; McKeithan TW; Chan WC
Hematol Oncol; 2012 Dec; 30(4):175-9. PubMed ID: 22170260
[TBL] [Abstract][Full Text] [Related]
3. Curcumin suppresses multiple DNA damage response pathways and has potency as a sensitizer to PARP inhibitor.
Ogiwara H; Ui A; Shiotani B; Zou L; Yasui A; Kohno T
Carcinogenesis; 2013 Nov; 34(11):2486-97. PubMed ID: 23825154
[TBL] [Abstract][Full Text] [Related]
4. DNA repair inhibition: a selective tumour targeting strategy.
Madhusudan S; Hickson ID
Trends Mol Med; 2005 Nov; 11(11):503-11. PubMed ID: 16214418
[TBL] [Abstract][Full Text] [Related]
5. Beyond PARP inhibitors: agents in pipelines target DNA repair mechanisms.
Maxmen A
J Natl Cancer Inst; 2010 Aug; 102(15):1110-1. PubMed ID: 20668266
[No Abstract] [Full Text] [Related]
6. Poly(ADP-ribose) polymerase inhibitors in cancer treatment: a clinical perspective.
Sandhu SK; Yap TA; de Bono JS
Eur J Cancer; 2010 Jan; 46(1):9-20. PubMed ID: 19926276
[TBL] [Abstract][Full Text] [Related]
7. Biomarker-Guided Development of DNA Repair Inhibitors.
Cleary JM; Aguirre AJ; Shapiro GI; D'Andrea AD
Mol Cell; 2020 Jun; 78(6):1070-1085. PubMed ID: 32459988
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of poly (ADP-ribose) polymerase activates ATM which is required for subsequent homologous recombination repair.
Bryant HE; Helleday T
Nucleic Acids Res; 2006; 34(6):1685-91. PubMed ID: 16556909
[TBL] [Abstract][Full Text] [Related]
9. DNA damage response pathways in tumor suppression and cancer treatment.
Liang Y; Lin SY; Brunicardi FC; Goss J; Li K
World J Surg; 2009 Apr; 33(4):661-6. PubMed ID: 19034564
[TBL] [Abstract][Full Text] [Related]
10. Role of autophagy in chemoresistance: regulation of the ATM-mediated DNA-damage signaling pathway through activation of DNA-PKcs and PARP-1.
Yoon JH; Ahn SG; Lee BH; Jung SH; Oh SH
Biochem Pharmacol; 2012 Mar; 83(6):747-57. PubMed ID: 22226932
[TBL] [Abstract][Full Text] [Related]
11. Modulation of DNA repair by pharmacological inhibitors of the PIKK protein kinase family.
Finlay MR; Griffin RJ
Bioorg Med Chem Lett; 2012 Sep; 22(17):5352-9. PubMed ID: 22835870
[TBL] [Abstract][Full Text] [Related]
12. Combination Platinum-based and DNA Damage Response-targeting Cancer Therapy: Evolution and Future Directions.
Basourakos SP; Li L; Aparicio AM; Corn PG; Kim J; Thompson TC
Curr Med Chem; 2017; 24(15):1586-1606. PubMed ID: 27978798
[TBL] [Abstract][Full Text] [Related]
13. Proteasome function is required for DNA damage response and fanconi anemia pathway activation.
Jacquemont C; Taniguchi T
Cancer Res; 2007 Aug; 67(15):7395-405. PubMed ID: 17671210
[TBL] [Abstract][Full Text] [Related]
14. Targeting DNA Damage Repair Pathways in Pancreatic Adenocarcinoma.
Das S; Cardin D
Curr Treat Options Oncol; 2020 Jun; 21(8):62. PubMed ID: 32601814
[TBL] [Abstract][Full Text] [Related]
15. Differential requirement for H2AX and 53BP1 in organismal development and genome maintenance in the absence of poly(ADP)ribosyl polymerase 1.
Orsburn B; Escudero B; Prakash M; Gesheva S; Liu G; Huso DL; Franco S
Mol Cell Biol; 2010 May; 30(10):2341-52. PubMed ID: 20231360
[TBL] [Abstract][Full Text] [Related]
16. Replication fork stability confers chemoresistance in BRCA-deficient cells.
Ray Chaudhuri A; Callen E; Ding X; Gogola E; Duarte AA; Lee JE; Wong N; Lafarga V; Calvo JA; Panzarino NJ; John S; Day A; Crespo AV; Shen B; Starnes LM; de Ruiter JR; Daniel JA; Konstantinopoulos PA; Cortez D; Cantor SB; Fernandez-Capetillo O; Ge K; Jonkers J; Rottenberg S; Sharan SK; Nussenzweig A
Nature; 2016 Jul; 535(7612):382-7. PubMed ID: 27443740
[TBL] [Abstract][Full Text] [Related]
17. Treating cancer by targeting a weakness.
Brody LC
N Engl J Med; 2005 Sep; 353(9):949-50. PubMed ID: 16135843
[No Abstract] [Full Text] [Related]
18. Breaking the DNA Damage Response via Serine/Threonine Kinase Inhibitors to Improve Cancer Treatment.
Rozpędek W; Pytel D; Nowak-Zduńczyk A; Lewko D; Wojtczak R; Diehl JA; Majsterek I
Curr Med Chem; 2019; 26(8):1425-1445. PubMed ID: 29345572
[TBL] [Abstract][Full Text] [Related]
19. The ATM-Chk2 and ATR-Chk1 pathways in DNA damage signaling and cancer.
Smith J; Tho LM; Xu N; Gillespie DA
Adv Cancer Res; 2010; 108():73-112. PubMed ID: 21034966
[TBL] [Abstract][Full Text] [Related]
20. Moving From Poly (ADP-Ribose) Polymerase Inhibition to Targeting DNA Repair and DNA Damage Response in Cancer Therapy.
Gourley C; Balmaña J; Ledermann JA; Serra V; Dent R; Loibl S; Pujade-Lauraine E; Boulton SJ
J Clin Oncol; 2019 Sep; 37(25):2257-2269. PubMed ID: 31050911
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]